Aiqun Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aiqun Ma has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Tingzhong Wang
Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
11 shared publications - Huaigen Wang
Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
4 shared publications Jing Liu
Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China
3 shared publicationsJing Zhang
Department of Cardiovascular Medicine Xi'an Jiaotong University Medical College First Affiliated Hospital Xi'an Shaanxi Province China
3 shared publications- Ling Bai
Department of Cardiology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
3 shared publications Linyan Wei
Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China
3 shared publications
Latest Publications
- Open Access
- 18 July 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
SDF-1 loaded dECM patch improves cardiac function in rats after myocardial ischemia
Background: Ischemic heart disease (IHD) remains a global health challenge, characterized by irreversible cardiomyocyte loss and pathological ventricular remodeling. Myocardial patches provide mechanical support for infarcted myocardium, but conventional biomaterials lack bioactive components to facilitate tissue regeneration. This study introduces a novel therapeutic strategy: a stromal cell-derived factor-1 (SDF-1)-loaded decellularized extracellular matrix (dECM) (SDF-dECM) patch addressing both biological and biomechanical deficiencies in myocardial repair. Methods: Porcine left ventricular dECM was decellularized, and SDF-1 was loaded to fabricate the SDF-dECM patch. The patch’s physicochemical properties, biocompatibility, and SDF-1 release profile were evaluated via hematoxylin and eosin/4’,6-diamidino-2-phenylindole staining, scanning electron microscopy, cytotoxicity assay, and enzyme-linked immunosorbent assay (ELISA). Transwell assays determined the chemotactic effect of SDF-1 on bone marrow mesenchymal stem cells (BMMSCs) and optimal concentration. Uniaxial tensile testing assessed mechanical properties. A finite element method (FEM) model was established to evaluate the patch’s mechanical support. In vivo, male Sprague-Dawley rats were randomly divided into four groups ( n = 15 per group): Sham, myocardial infarction (MI), MI + dECM, and MI + SDF-dECM. Echocardiography, histochemical staining, and immunofluorescence staining were used to assess cardiac function, tissue morphology, BMMSCs homing, microvascular regeneration, and cardiomyocyte apoptosis. The paracrine mechanism of BMMSCs was evaluated via ELISA and functional assays. Results: The SDF-dECM patch achieved successful decellularization, maintained a porous structure (50-150 μm pore size), exhibited favorable biphasic mechanical properties, and exhibited sustained SDF-1 release for 28 days. SDF-1 effectively induced BMMSCs migration via the SDF-1/CXCR4 axis, with 200 ng/mL as the optimal concentration. In vivo, the SDF-dECM patch significantly enhanced endogenous BMMSCs homing to the peri-infarct area, promoted peri-infarct microvascular regeneration, and inhibited cardiomyocyte apoptosis. BMMSCs-conditioned medium contained high levels of vascular endothelial growth factor and hepatocyte growth factor, exerting pro-angiogenic and anti-apoptotic effects. FEM simulations showed the patch reduced infarct zone wall stress and stress concentration. Echocardiography and histological analysis confirmed the SDF-dECM patch significantly improved cardiac function, reduced infarct size and alleviated myocardial fibrosis. Conclusion: The dual-functional SDF-dECM patch integrates sustained SDF-1 delivery for endogenous BMMSCs mobilization and biomechanical support to mitigate ventricular remodeling. The synergy between biological activity and mechanical stabilization provides a promising therapeutic strategy for IHD, overcoming limitations of conventional biomaterials.
- 18 July 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessSDF-1 loaded dECM patch improves cardiac function in rats after myocardial ischemia
Background: Ischemic heart disease (IHD) remains a global health challenge, characterized by irreversible cardiomyocyte loss and pathological ventricular remodeling. Myocardial patches provide mechanical support for infarcted myocardium, but conventional biomaterials lack bioactive components to facilitate tissue regeneration. This study introduces a novel therapeutic strategy: a stromal cell-derived factor-1 (SDF-1)-loaded decellularized extracellular matrix (dECM) (SDF-dECM) patch addressing both biological and biomechanical deficiencies in myocardial repair. Methods: Porcine left ventricular dECM was decellularized, and SDF-1 was loaded to fabricate the SDF-dECM patch. The patch’s physicochemical properties, biocompatibility, and SDF-1 release profile were evaluated via hematoxylin and eosin/4’,6-diamidino-2-phenylindole staining, scanning electron microscopy, cytotoxicity assay, and enzyme-linked immunosorbent assay (ELISA). Transwell assays determined the chemotactic effect of SDF-1 on bone marrow mesenchymal stem cells (BMMSCs) and optimal concentration. Uniaxial tensile testing assessed mechanical properties. A finite element method (FEM) model was established to evaluate the patch’s mechanical support. In vivo, male Sprague-Dawley rats were randomly divided into four groups ( n = 15 per group): Sham, myocardial infarction (MI), MI + dECM, and MI + SDF-dECM. Echocardiography, histochemical staining, and immunofluorescence staining were used to assess cardiac function, tissue morphology, BMMSCs homing, microvascular regeneration, and cardiomyocyte apoptosis. The paracrine mechanism of BMMSCs was evaluated via ELISA and functional assays. Results: The SDF-dECM patch achieved successful decellularization, maintained a porous structure (50-150 μm pore size), exhibited favorable biphasic mechanical properties, and exhibited sustained SDF-1 release for 28 days. SDF-1 effectively induced BMMSCs migration via the SDF-1/CXCR4 axis, with 200 ng/mL as the optimal concentration. In vivo, the SDF-dECM patch significantly enhanced endogenous BMMSCs homing to the peri-infarct area, promoted peri-infarct microvascular regeneration, and inhibited cardiomyocyte apoptosis. BMMSCs-conditioned medium contained high levels of vascular endothelial growth factor and hepatocyte growth factor, exerting pro-angiogenic and anti-apoptotic effects. FEM simulations showed the patch reduced infarct zone wall stress and stress concentration. Echocardiography and histological analysis confirmed the SDF-dECM patch significantly improved cardiac function, reduced infarct size and alleviated myocardial fibrosis. Conclusion: The dual-functional SDF-dECM patch integrates sustained SDF-1 delivery for endogenous BMMSCs mobilization and biomechanical support to mitigate ventricular remodeling. The synergy between biological activity and mechanical stabilization provides a promising therapeutic strategy for IHD, overcoming limitations of conventional biomaterials.
- Open Access
- 13 December 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (50) , e40875
A potential pathogenic mutation of LAMA4 in a Chinese family with dilated cardiomyopathy and conduction system disease
Dilated cardiomyopathy (DCM) is characterized by ventricular dilation and poor systolic function. Approximately half of idiopathic DCM cases are assigned to genetic causes in familial or apparently sporadic cases, and more than 50 genes are reported to cause DCM. However, genetic basis of most DCM patients still keeps unknown and require further study. Clinical data, family histories, and blood samples were collected from the proband and family members in a Chinese family presenting with DCM and conduction system disease. A genetic analysis was performed using next generation sequencing (NGS). Bioinformatic analysis was performed to predict the pathogenic consequence of gene mutation. A missense heterozygous mutation c.652G > A (p.G218R) in Laminin Subunit Alpha-4 (LAMA4) gene was identified in proband and his 2 brothers with relevant clinical symptoms. Individuals without carrying this mutation in this family had no symptoms or cardiac structural abnormality related to DCM or conduction system disease. The p.G218R mutation is located in a conservative area within the laminin epidermal growth factor (EGF)-like domain of LAMA4 with uncertain significance in ClinVar archive. Bioinformatic analysis predicted p.G218R mutation as deleterious and pathogenic damaging in DCM patients. Our results reported a potential pathogenic mutation associated with DCM, which may provide further insight into genetic contributions of LAMA4 gene mutations to DCM phenotypes.
- 13 December 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (50) , e40875
Open AccessA potential pathogenic mutation of LAMA4 in a Chinese family with dilated cardiomyopathy and conduction system disease
Dilated cardiomyopathy (DCM) is characterized by ventricular dilation and poor systolic function. Approximately half of idiopathic DCM cases are assigned to genetic causes in familial or apparently sporadic cases, and more than 50 genes are reported to cause DCM. However, genetic basis of most DCM patients still keeps unknown and require further study. Clinical data, family histories, and blood samples were collected from the proband and family members in a Chinese family presenting with DCM and conduction system disease. A genetic analysis was performed using next generation sequencing (NGS). Bioinformatic analysis was performed to predict the pathogenic consequence of gene mutation. A missense heterozygous mutation c.652G > A (p.G218R) in Laminin Subunit Alpha-4 (LAMA4) gene was identified in proband and his 2 brothers with relevant clinical symptoms. Individuals without carrying this mutation in this family had no symptoms or cardiac structural abnormality related to DCM or conduction system disease. The p.G218R mutation is located in a conservative area within the laminin epidermal growth factor (EGF)-like domain of LAMA4 with uncertain significance in ClinVar archive. Bioinformatic analysis predicted p.G218R mutation as deleterious and pathogenic damaging in DCM patients. Our results reported a potential pathogenic mutation associated with DCM, which may provide further insight into genetic contributions of LAMA4 gene mutations to DCM phenotypes.
- Open Access
- 1 April 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 1713-1722
Nomogram to Predict Outcomes After Staged Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease
Objective: Approximately 50% of ST-segment elevation myocardial infarction (STEMI) patients have multivessel coronary artery disease (MVD). The management strategy for these patients remains controversial. This study aimed to develop predictive models and nomogram of outcomes in STEMI patients with MVD for better identification and classification. Methods: The least absolute shrinkage and selection operator (LASSO) method was used to select the features most significantly associated with the outcomes. A Cox regression model was built using the selected variables. One nomogram was computed from each model, and individual risk scores were obtained by applying the nomograms to the cohort. After regrouping patients based on nomogram risk scores into low- and high-risk groups, we used the Kaplan–Meier method to perform survival analysis. Results: The C-index of the major adverse cardiovascular event (MACE)-free survival model was 0· 68 (95% CI 0· 62– 0· 74) and 0· 65 [0· 62– 0· 68]) at internal validation, and that of the overall survival model was 0· 75 (95% CI 0· 66– 0· 84) and (0· 73 [0· 65– 0· 81]). The predictions of both models correlated with the observed outcomes. Low-risk patients had significantly lower probabilities of 1-year or 3-year MACEs (4% versus 11%, P= 0.003; 7% versus 15%, P=0.01, respectively) and 1-year or 3-year all-cause death (1% versus 3%, P=0.048; 2% versus 7%, respectively, P=0.001) than high-risk patients. Conclusion: Our nomograms can be used to predict STEMI and MVD outcomes in a simple and practical way for patients who undergo primary PCI for culprit vessels and staged PCI for non-culprit vessels.
- 1 April 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 1713-1722
Open AccessNomogram to Predict Outcomes After Staged Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease
Objective: Approximately 50% of ST-segment elevation myocardial infarction (STEMI) patients have multivessel coronary artery disease (MVD). The management strategy for these patients remains controversial. This study aimed to develop predictive models and nomogram of outcomes in STEMI patients with MVD for better identification and classification. Methods: The least absolute shrinkage and selection operator (LASSO) method was used to select the features most significantly associated with the outcomes. A Cox regression model was built using the selected variables. One nomogram was computed from each model, and individual risk scores were obtained by applying the nomograms to the cohort. After regrouping patients based on nomogram risk scores into low- and high-risk groups, we used the Kaplan–Meier method to perform survival analysis. Results: The C-index of the major adverse cardiovascular event (MACE)-free survival model was 0· 68 (95% CI 0· 62– 0· 74) and 0· 65 [0· 62– 0· 68]) at internal validation, and that of the overall survival model was 0· 75 (95% CI 0· 66– 0· 84) and (0· 73 [0· 65– 0· 81]). The predictions of both models correlated with the observed outcomes. Low-risk patients had significantly lower probabilities of 1-year or 3-year MACEs (4% versus 11%, P= 0.003; 7% versus 15%, P=0.01, respectively) and 1-year or 3-year all-cause death (1% versus 3%, P=0.048; 2% versus 7%, respectively, P=0.001) than high-risk patients. Conclusion: Our nomograms can be used to predict STEMI and MVD outcomes in a simple and practical way for patients who undergo primary PCI for culprit vessels and staged PCI for non-culprit vessels.
- Open Access
- 25 May 2023
- Published by Frontiers Media SA in Frontiers in Epidemiology
- Vol. 3, 1048515
The burden of cardiovascular diseases attributable to metabolic risk factors and its change from 1990 to 2019: a systematic analysis and prediction
Background: Metabolic disorders are the most important risk factors for cardiovascular diseases (CVDs). The purpose of this study was to systematically analyze and summarize the most recent data by age, sex, region, and time, and to forecast the future burden of diseases.Methods: Data on the burden of CVDs associated with metabolic risk factors were obtained from the Global Burden of Disease (GBD) Study 2019; and then the burden of disease was assessed using the numbers and age-standardized rates (ASR) of deaths, years of life lost (YLLs), years of life lived with disability (YLDs), and disability-adjusted life-years (DALYs) and analyzed for temporal changes, differences in age, region, sex, and socioeconomic aspects; finally, the burden of disease was predicted using an autoregressive integrated moving average (ARIMA) model.Results: From 1990 to 2019, the numbers of deaths, DALYs, YLDs, and YLLs attributed to metabolic risk factors increased by 59.3%, 51.0%, 104.6%, and 47.8%, respectively. The ASR decreased significantly. The burden of metabolic risk factor-associated CVDs was closely related to socioeconomic position and there were major geographical variations; additionally, men had a significantly greater disease burden than women, and the peak shifted later based on the age group. We predicted that the numbers of deaths and DALYs would reach 16.5 million and 324.8 million, respectively, by 2029.Conclusions: The global burden of CVDs associated with metabolic risk factors is considerable and still rising, and more effort is needed to intervene in metabolic disorders.
- 25 May 2023
- Published by Frontiers Media SA in Frontiers in Epidemiology
- Vol. 3, 1048515
Open AccessThe burden of cardiovascular diseases attributable to metabolic risk factors and its change from 1990 to 2019: a systematic analysis and prediction
Background: Metabolic disorders are the most important risk factors for cardiovascular diseases (CVDs). The purpose of this study was to systematically analyze and summarize the most recent data by age, sex, region, and time, and to forecast the future burden of diseases.Methods: Data on the burden of CVDs associated with metabolic risk factors were obtained from the Global Burden of Disease (GBD) Study 2019; and then the burden of disease was assessed using the numbers and age-standardized rates (ASR) of deaths, years of life lost (YLLs), years of life lived with disability (YLDs), and disability-adjusted life-years (DALYs) and analyzed for temporal changes, differences in age, region, sex, and socioeconomic aspects; finally, the burden of disease was predicted using an autoregressive integrated moving average (ARIMA) model.Results: From 1990 to 2019, the numbers of deaths, DALYs, YLDs, and YLLs attributed to metabolic risk factors increased by 59.3%, 51.0%, 104.6%, and 47.8%, respectively. The ASR decreased significantly. The burden of metabolic risk factor-associated CVDs was closely related to socioeconomic position and there were major geographical variations; additionally, men had a significantly greater disease burden than women, and the peak shifted later based on the age group. We predicted that the numbers of deaths and DALYs would reach 16.5 million and 324.8 million, respectively, by 2029.Conclusions: The global burden of CVDs associated with metabolic risk factors is considerable and still rising, and more effort is needed to intervene in metabolic disorders.
- Open Access
- 13 February 2023
- Published by Wiley in Clinical Cardiology
- Vol. 46 (4) , 390-396
Prognosis and subtype analysis of left ventricular noncompaction in adults: A retrospective multicenter study
Background: Left ventricular noncompaction (LVNC) is a heterogeneous myocardial disorder with an uncertain prognosis. There was a lack of studies on LVNC subtypes at present. This study sought to identify the prognosis of the overall population of LVNC and to describe the distribution of different subtypes and compare their prognosis.Hypothesis: Patients with different subtypes of LVNC may have different prognoses.Methods: Patients who fulfilled the Jenni criteria and/or Petersen criteria were included. Major adverse cardiovascular events (MACE) were defined as a combination of heart failure (HF) hospitalization and all‐cause mortality.Results: A total of 200 patients from four hospitals were included. The mean age at diagnosis was 48.2 years, and 61.5% of the patients were male. Left ventricular ejection fraction (LVEF) < 50% was present in 54% of the patients. Over a mean retrospective time period of 22.2 months, 47 (23.5%) patients experienced MACE. Age (hazard ratio [HR] 1.03; 95% confidence interval [CI] 1.01–1.06; p = .004), LVEF < 50% (HR 2.32; 95% CI 1.09–4.91; p = .028) and ventricular tachycardia/ventricular fibrillation (HR 2.17; 95% CI 1.08–4.37; p = .03) were significantly associated with the risk of MACE. The most common subtype was dilated LVNC (51.3%), followed by benign LVNC (21.3%) and LVNC with arrhythmias (10.5%). Patients with dilated LVNC had significantly increased cumulative incidence of MACE, HF hospitalization, and all‐cause mortality (p < .05).Conclusions: Age, LVEF < 50%, and ventricular tachycardia/ventricular fibrillation were independent risk factors for prognosis of LVNC. The most common subtype was dilated LVNC, which had a worse prognosis.
- 13 February 2023
- Published by Wiley in Clinical Cardiology
- Vol. 46 (4) , 390-396
Open AccessPrognosis and subtype analysis of left ventricular noncompaction in adults: A retrospective multicenter study
Background: Left ventricular noncompaction (LVNC) is a heterogeneous myocardial disorder with an uncertain prognosis. There was a lack of studies on LVNC subtypes at present. This study sought to identify the prognosis of the overall population of LVNC and to describe the distribution of different subtypes and compare their prognosis.Hypothesis: Patients with different subtypes of LVNC may have different prognoses.Methods: Patients who fulfilled the Jenni criteria and/or Petersen criteria were included. Major adverse cardiovascular events (MACE) were defined as a combination of heart failure (HF) hospitalization and all‐cause mortality.Results: A total of 200 patients from four hospitals were included. The mean age at diagnosis was 48.2 years, and 61.5% of the patients were male. Left ventricular ejection fraction (LVEF) < 50% was present in 54% of the patients. Over a mean retrospective time period of 22.2 months, 47 (23.5%) patients experienced MACE. Age (hazard ratio [HR] 1.03; 95% confidence interval [CI] 1.01–1.06; p = .004), LVEF < 50% (HR 2.32; 95% CI 1.09–4.91; p = .028) and ventricular tachycardia/ventricular fibrillation (HR 2.17; 95% CI 1.08–4.37; p = .03) were significantly associated with the risk of MACE. The most common subtype was dilated LVNC (51.3%), followed by benign LVNC (21.3%) and LVNC with arrhythmias (10.5%). Patients with dilated LVNC had significantly increased cumulative incidence of MACE, HF hospitalization, and all‐cause mortality (p < .05).Conclusions: Age, LVEF < 50%, and ventricular tachycardia/ventricular fibrillation were independent risk factors for prognosis of LVNC. The most common subtype was dilated LVNC, which had a worse prognosis.
- Open Access
- 11 October 2022
- Published by Springer Nature in BMC Medical Genomics
- Vol. 15 (1) , 1-8
Left ventricular non-compaction cardiomyopathy associated with the PRKAG2 mutation
Left ventricular non-compaction cardiomyopathy (LVNC) is one of the most common inherited cardiovascular diseases. The genetic backgrounds of most LVNC patients are not fully understood. We collected clinical data, family histories, and blood samples and performed genetic analysis using next-generation sequencing (NGS) from a Chinese family of 15 subjects. Clinically LVNC affected subjects showed marked cardiac phenotype heterogeneity. We found that these subjects with LVNC carried a missense heterozygous genetic mutation c.905G>A (p.R302Q) in γ2 subunit of AMP-activated protein kinase (PRKAG2) gene through NGS. Individuals without this mutation showed no symptoms or cardiac structural abnormalities related to LVNC. One subject was the victim of sudden cardiac death. To sum up, PRKAG2 mutation c.905G>A (p.R302Q) caused familial LVNC. Our results described a potentially pathogenic mutation associated with LVNC, which may further extend the spectrum of LVNC phenotypes related to PRKAG2 gene mutations.
- 11 October 2022
- Published by Springer Nature in BMC Medical Genomics
- Vol. 15 (1) , 1-8
Open AccessLeft ventricular non-compaction cardiomyopathy associated with the PRKAG2 mutation
Left ventricular non-compaction cardiomyopathy (LVNC) is one of the most common inherited cardiovascular diseases. The genetic backgrounds of most LVNC patients are not fully understood. We collected clinical data, family histories, and blood samples and performed genetic analysis using next-generation sequencing (NGS) from a Chinese family of 15 subjects. Clinically LVNC affected subjects showed marked cardiac phenotype heterogeneity. We found that these subjects with LVNC carried a missense heterozygous genetic mutation c.905G>A (p.R302Q) in γ2 subunit of AMP-activated protein kinase (PRKAG2) gene through NGS. Individuals without this mutation showed no symptoms or cardiac structural abnormalities related to LVNC. One subject was the victim of sudden cardiac death. To sum up, PRKAG2 mutation c.905G>A (p.R302Q) caused familial LVNC. Our results described a potentially pathogenic mutation associated with LVNC, which may further extend the spectrum of LVNC phenotypes related to PRKAG2 gene mutations.
- Open Access
- 30 July 2022
- Published by International Society of Global Health in Journal of Global Health
- Vol. 12, 04041
The burden of alcoholic cardiomyopathy in China and different regions around the world
Alcoholic cardiomyopathy (ACM), first described in 1877 [1], is a myocardial disease caused by long-term heavy alcohol consumption. It is characterized by impaired ventricular dilation and contractility with normal or reduced ventricular wall thickness [2,3]. Alcohol abuse is an important cause of non-ischemic cardiomyopathy, accounting for 10% cases of dilated cardiomyopathies [4]. Extensive studies have […]
- 30 July 2022
- Published by International Society of Global Health in Journal of Global Health
- Vol. 12, 04041
Open AccessThe burden of alcoholic cardiomyopathy in China and different regions around the world
Alcoholic cardiomyopathy (ACM), first described in 1877 [1], is a myocardial disease caused by long-term heavy alcohol consumption. It is characterized by impaired ventricular dilation and contractility with normal or reduced ventricular wall thickness [2,3]. Alcohol abuse is an important cause of non-ischemic cardiomyopathy, accounting for 10% cases of dilated cardiomyopathies [4]. Extensive studies have […]
- Top Cited Papers
- 1 April 2022
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 32 (4) , 897-907
Cardiovascular disease burden attributable to dietary risk factors from 1990 to 2019: A systematic analysis of the Global Burden of Disease study
- 1 April 2022
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 32 (4) , 897-907
Top Cited PapersCardiovascular disease burden attributable to dietary risk factors from 1990 to 2019: A systematic analysis of the Global Burden of Disease study
- Open Access
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 55 (1) , e11850
The LDL/HDL ratio predicts long-term risk of coronary revascularization in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: a cohort study
Clinical indicators do not adequately predict the long-term prognosis of patients with ST-segment elevation myocardial infarction (STEMI) following percutaneous coronary intervention (PCI). The low-density lipoprotein (LDL)/high-density lipoprotein (HDL) ratio is expected to be a reliable predictor of the long-term prognosis of these patients. This study aimed to explore the correlation between the LDL/HDL ratio and long-term prognosis in STEMI patients undergoing PCI. Patients with confirmed STEMI who underwent PCI in 7 hospitals in China from January 2009 to December 2011 were enrolled. Information about clinical endpoints, including all-cause death and major adverse cardiovascular events, was collected. Overall, 915 patients were included for analysis, the average follow-up time was 112.2 months. According to the LDL/HDL ratio, the patients were divided into 3 groups using the three-quantile method: low (LDL/HDL≤1.963), medium (1.963<LDL/HDL<2.595), and high (LDL/HDL≥2.595) LDL/HDL groups. The rate of coronary revascularization was higher in the high LDL/HDL group (28.52%) than in the low (17.38%, P=0.001) and medium (19.34%, P=0.010) LDL/HDL groups. The hazard ratio of coronary revascularization was significantly higher in the high LDL/HDL group than in the low (P=0.007) and medium (P=0.004) LDL/HDL groups. Increased LDL/HDL ratio was an independent risk factor for long-term coronary revascularization in STEMI patients undergoing PCI (HR=1.231, 95%CI: 1.023-1.482, P=0.028). These findings suggest that an increased LDL/HDL ratio was an independent risk factor for long-term coronary revascularization in STEMI patients undergoing PCI. The risk of coronary revascularization was significantly increased in patients with LDL/HDL≥2.595.
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 55 (1) , e11850
Open AccessThe LDL/HDL ratio predicts long-term risk of coronary revascularization in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: a cohort study
Clinical indicators do not adequately predict the long-term prognosis of patients with ST-segment elevation myocardial infarction (STEMI) following percutaneous coronary intervention (PCI). The low-density lipoprotein (LDL)/high-density lipoprotein (HDL) ratio is expected to be a reliable predictor of the long-term prognosis of these patients. This study aimed to explore the correlation between the LDL/HDL ratio and long-term prognosis in STEMI patients undergoing PCI. Patients with confirmed STEMI who underwent PCI in 7 hospitals in China from January 2009 to December 2011 were enrolled. Information about clinical endpoints, including all-cause death and major adverse cardiovascular events, was collected. Overall, 915 patients were included for analysis, the average follow-up time was 112.2 months. According to the LDL/HDL ratio, the patients were divided into 3 groups using the three-quantile method: low (LDL/HDL≤1.963), medium (1.963<LDL/HDL<2.595), and high (LDL/HDL≥2.595) LDL/HDL groups. The rate of coronary revascularization was higher in the high LDL/HDL group (28.52%) than in the low (17.38%, P=0.001) and medium (19.34%, P=0.010) LDL/HDL groups. The hazard ratio of coronary revascularization was significantly higher in the high LDL/HDL group than in the low (P=0.007) and medium (P=0.004) LDL/HDL groups. Increased LDL/HDL ratio was an independent risk factor for long-term coronary revascularization in STEMI patients undergoing PCI (HR=1.231, 95%CI: 1.023-1.482, P=0.028). These findings suggest that an increased LDL/HDL ratio was an independent risk factor for long-term coronary revascularization in STEMI patients undergoing PCI. The risk of coronary revascularization was significantly increased in patients with LDL/HDL≥2.595.
- 1 January 2022
- Published by Elsevier in European Journal of Pharmacology
- Vol. 915, 174601
LncRNA SNHG16 accelerates atherosclerosis and promotes ox-LDL-induced VSMC growth via the miRNA-22–3p/HMGB2 axis
- 1 January 2022
- Published by Elsevier in European Journal of Pharmacology
- Vol. 915, 174601
LncRNA SNHG16 accelerates atherosclerosis and promotes ox-LDL-induced VSMC growth via the miRNA-22–3p/HMGB2 axis